

Transthyretin (ATTR or Prealbumin or TBPA or TTR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/TC087ADCB8E3EN.html>

Date: September 2022

Pages: 85

Price: US\$ 3,500.00 (Single User License)

ID: TC087ADCB8E3EN

Abstracts

Transthyretin (ATTR or Prealbumin or TBPA or TTR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Transthyretin is a transport protein. It transports thyroid hormones in the plasma and cerebrospinal fluid, and also transports retinol (vitamin A) in the plasma. The diseases caused by mutations include amyloidotic polyneuropathy, euthyroid hyperthyroxinaemia, amyloidotic vitreous opacities, cardiomyopathy, oculoleptomeningeal amyloidosis, meningocerebrovascular amyloidosis and carpal tunnel syndrome.

Transthyretin (ATTR or Prealbumin or TBPA or TTR) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 4, 3 and 2 respectively. Similarly, the universities portfolio in Phase III stages comprises 1 molecule, respectively. Report covers products from therapy areas Metabolic Disorders, Ophthalmology, Central Nervous System, Gastrointestinal, Immunology and Infectious Disease which include indications Familial Amyloid Neuropathies, Familial Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Amyloidosis, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Crohn's Disease (Regional Enteritis), Glaucoma, Juvenile Macular Degeneration (Stargardt Disease), Keratoconjunctivitis Sicca (Dry Eye), Multiple Sclerosis, Rheumatoid Arthritis, Ulcerative Colitis and Unspecified Ophthalmological

Disorders.

The latest report Transthyretin - Drugs In Development, 2022, outlays comprehensive information on the Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Transthyretin (ATTR or Prealbumin or TBPA or TTR)

The report reviews Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics and enlists all their major and minor projects

The report assesses Transthyretin (ATTR or Prealbumin or TBPA or TTR)

targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transthyretin (ATTR or Prealbumin or TBPA or TTR) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transthyretin (ATTR or Prealbumin or TBPA or TTR) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Overview

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Companies Involved in
Therapeutics Development

ADRx Inc

Akcea Therapeutics Inc

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Autotac Bio Inc

BridgeBio Pharma Inc

BSIM Therapeutics SA

Corino Therapeutics Inc

Covalent Bioscience Inc

Galmed Pharmaceuticals Ltd

Novo Nordisk AS

Proclara Biosciences Inc

Regeneron Pharmaceuticals Inc

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Drug Profiles

acoramidis hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

ALNTTRSC-04 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Amilo-5MER - Drug Profile

Product Description

Mechanism Of Action

History of Events

Antibody to Inhibit TTR for Familial Transthyretin Amyloidosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

ATC-202 - Drug Profile

Product Description

Mechanism Of Action

doxycycline hyclate - Drug Profile

Product Description

Mechanism Of Action

History of Events

eplontersen sodium - Drug Profile

Product Description

Mechanism Of Action

History of Events

inotersen sodium - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody for Familial Amyloid Cardiomyopathy - Drug Profile

Product Description

Mechanism Of Action

History of Events

NI-006 - Drug Profile

Product Description

Mechanism Of Action

History of Events

NPT-189 - Drug Profile

Product Description

Mechanism Of Action

History of Events

NTLA-2001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

patisiran - Drug Profile

Product Description

Mechanism Of Action

History of Events

PRX-004 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Transthyretin for Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

tafamidis meglumine - Drug Profile

Product Description

Mechanism Of Action

History of Events

tolcapone - Drug Profile

Product Description

Mechanism Of Action

History of Events

vutrisiran - Drug Profile

Product Description

Mechanism Of Action

History of Events

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Dormant Products

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Discontinued Products

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Product Development Milestones

Featured News & Press Releases

Aug 18, 2022: Alnylam to present data from the APOLLO-B phase 3 study of patisiran in patients with ATTR amyloidosis with cardiomyopathy at the 18th International Symposium on amyloidosis

Aug 03, 2022: Alnylam reports positive topline results from APOLLO-B phase 3 study of patisiran in patients with ATTR amyloidosis with cardiomyopathy

Jul 22, 2022: Alnylam receives positive CHMP opinion for vutrisiran for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy

Jul 20, 2022: Orsini Specialty Pharmacy selected as limited distribution partner for AMVUTTRA (vutrisiran)

Jun 24, 2022: Intellia and Regeneron present updated interim data from phase 1 Study of CRISPR-based NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis

demonstrating that deep serum TTR reductions remained durable after a single dose
Jun 22, 2022: AstraZeneca-Ionis' eplontersen meets endpoints in Phase III ATTRv-PN trial

Jun 13, 2022: Alnylam announces FDA approval of AMVUTTRA (vutrisiran), an RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Jun 08, 2022: Intellia Therapeutics to present updated interim clinical data from ongoing phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis at the International Liver Congress 2022

May 23, 2022: Alnylam presents new 18-month results from exploratory cardiac endpoints in HELIOS-A phase 3 study of investigational vutrisiran

Apr 04, 2022: Alnylam announces 3-Month extension of review period for New Drug Application for Vutrisiran

Apr 03, 2022: BridgeBio Pharma presents updated results from phase 2 open-label extension study of Acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM)

Mar 28, 2022: BridgeBio Pharma to present updated results from phase 2 open-label extension study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Mar 01, 2022: Intellia, Regeneron report positive Phase I transthyretin amyloidosis data

Feb 17, 2022: Intellia Therapeutics announces two upcoming investor events in February 2022

Jan 24, 2022: Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by ADRx Inc, 2022
Pipeline by Akcea Therapeutics Inc, 2022
Pipeline by Alexion Pharmaceuticals Inc, 2022
Pipeline by Alnylam Pharmaceuticals Inc, 2022
Pipeline by Autotac Bio Inc, 2022
Pipeline by BridgeBio Pharma Inc, 2022
Pipeline by BSIM Therapeutics SA, 2022
Pipeline by Corino Therapeutics Inc, 2022
Pipeline by Covalent Bioscience Inc, 2022
Pipeline by Galmed Pharmaceuticals Ltd, 2022
Pipeline by Novo Nordisk AS, 2022
Pipeline by Proclara Biosciences Inc, 2022
Pipeline by Regeneron Pharmaceuticals Inc, 2022
Dormant Projects, 2022
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Transthyretin (ATTR or Prealbumin or TBPA or TTR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/TC087ADCB8E3EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TC087ADCB8E3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

